gland pharma glp-1 manufacturing capacity The boom: Challenges, trends, and CapEx strategies for manufacturers GLP-1s and the Unintended Consequences

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management in adults (Mounjaro) and chronic weight management in adults with BMI 30 kg/m or 27 kg/m with at least one weight-related comorbidity (Zepbound)

Tune in to Primes Pharmacy Friends podcast episode on MASH to learn more

Who is it for: Compounded liraglutide is recommended for pre-, peri- and post-menopausal women who qualify for weight loss treatments and would benefit from a holistic platform with 24/7 access to physicians and a supportive community of experts and other women in this life stage

Patients interested in the full scope of what peptide science offers can explore the relationship between peptides and semaglutide or investigate supportive therapies for gut health that may complement weight management efforts

References Tsoi, K